DDInter740 DDInter833
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Flecainide {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Flecainide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)